Fri, 25 Feb 2022



**Oriental Patron Research** 

## Equity Research Chemicals/ China

#### John Siah

+852 2135 0248 john.siah@oriental-patron.com.hk

# **OP Express**

## Not rated


Close price: HK\$1.31

**Key Data** 

HKEx code			1986 HK
12 Months High	(HK\$)		1.86
12 Month Low	(HK\$)		1.12
3M Avg Dail Vol.	(mn)		1.25
Issue Share	(mn)		1,026.26
Market Cap	(HK\$mn)		1,344.39
Fiscal Year			12/2020
Major shareholder	(s)	Mr	Ge Yi(51 97%)

Source: Company data, Bloomberg, OP Research Closing price are as of 24/02/2022

## **Price Chart**



Absolute %	-3.0	-13.2	-5.1
Rel. MSCI China %	1.8	-2.2	7.0
PE Chart			



### Company profile

Tsaker Chemical Group Ltd develops chemicals used for pigment products. The Company sells its products to the pharmaceutical and agricultural chemical manufacturing industry.

# Tsaker Chem (1986 HK)

## Battery business started to bear fruit

- Tsaker expects FY21 net profit to grow at least 52% yoy to over RMB220mn, thanks to (1) the increase in sales volume of dye and pigment intermediates, and (2)significant increase in price and sales volume of iron phosphate
- Price of iron phosphate has surged 70% since Sep 21, expecting battery business to break even in FY21
- Battery business may act as a trigger for re-rating

Battery business is getting on the right track. We believe a 70%+ increase in price of iron phosphate since Sep 21 will bring Tsaker's battery business to turnaround. We expect the price of iron phosphate will stay high in the near term given (1) strong battery demand from EVs, and (2) lithium iron phosphate ("LFP") battery becomes the mainstream battery for EVs. Tsaker has been gradually mass producing iron phosphate from 2H21 after it upgraded the production facilities. Looking forward, Tsaker is working to raise the annual production capacity of iron phosphate from 20,000 tonnes to 70,000 tonnes by 2024 to meet surging demand for LFP battery.

Overwhelming market share for major products. Tsaker is the global market leader in DSD Acid, DMSS and DMAS, the dye and pigment intermediates that are widely used in industrial products and consumer goods. Tsaker has the pricing power to shift the rising costs to customers. We understand it has increased prices of major products from 4Q21. Besides, we expect a mild GPM improvement for chemical intermediates in FY21E amid higher sales.

BPDA will benefit from the growing polyimide film industry chain in China. BPDA is a chemical intermediate for the production of polyimide film which is widely used in semi-conductor, microelectronics, aerospace and etc. The Company has started to construct production lines for BPDA with 500 tonnes annual capacity, expecting to complete in Jun 2022.

Battery business may act as a trigger for re-rating. Tsaker is trading at an undemanding FY21E PER of 5.1x when comparing to the 5 year average PER of 22.4x. We argue that investors have overlooked the Company's battery business which deserve a higher P/E multiple. We project battery business will contribute net profit of RMB40mn in 22E. The value of the battery business could reach RMB900mn (or HK\$1.1bn) based on Chinese battery material manufacturers' average PER (23x) in FY22E.


**Risk:** (1) Price competition, (2) shrinking demand for LFP battery, (3) Weakening market leadership for chemical intermediates.

Exhibit 1: Financial Summary										
Year to Dec (RMB\$ mn)	FY17	FY18	FY19	FY20						
Revenue	1,247.4	1,515.9	1,818.3	1,275.3						
Growth (%)	+19.8	+21.5	+20.0	-29.9						
Net profit	136.1	222.9	517.9	144.9						
Growth (%)	+12.6	+63.7	+132.4	-72.0						
Gross margin (%)	29.1	34.6	57.2	34.9						
Profit margin (%)	10.9	14.7	28.5	11.4						
EPS(RMB)	0.130	0.210	0.500	0.140						
ROE (%)	13.0	18.1	33.6	8.4						
P/E (x)	10.1	6.2	2.6	9.4						
P/B (x)	1.2	1.0	0.8	0.8						
Yield (%)	3.0	4.9	7.0	3.7						


Source: Bloomberg, OP Research



Exhibit 2: LFP battery has become the mainstream battery for EVs in China thanks to the cost advantage




# Battery installation of EVs in China (GW, Jan 21- Jan 22)




Sources: EnergyTrend, China Automotive Battery Innovation Alliance, OP Research

Exhibit 3: Price of LFP battery raw materials have jumped ~70% since Sep 21



## Price of lithium iron phosphate from 2021




\*Iron phosphate is the main ingredient of lithium iron phosphate

Sources: ICCSINO, Bloomberg, OP Research

Exhibit 4: The strong growth of new capacity of iron phosphate matches to the expected growth in battery demand for EVs and energy storage

Market expects a surging battery demand for electric vehicle and energy storage in the next ten years(GWh, cumulative)

Projection on new production capacity of iron phosphate (thousand tonnes) based on the expansion plans disclosed by Chinese companies, who have engage in the production of iron phosphate




Sources: Wood MacKenzie, open sources, Company

The production capacity of iron phosphate is expected to grow significantly in next few years based on the announced expansion plans of A-share and HK-listed companies. However, it is not easy for manufacturers to consistently produce high quality iron phosphate. We understand that some companies have encountered problems with mass production of iron phosphate. This has slowed down the growth of new capacity in the short term.



Exhibit 5: We expect Tsaker's battery business to contribute net profit of RMB40mn in FY22E and RMB140mn after it has executed the expansion plan and reached full production capacity




Sources: Company, OP Research

Exhibit 6: The value of Tsaker's battery business could reach RMB900mn(or HK\$1.1bn) based on the average FY22E PER of A shares companies who engage in manufacturing of iron phosphate and battery raw materials

			Mkt cap			
Name	Ticker	Price	(US\$m)	PER Hist (x)	PER 21E (x)	PER 22E (x)
Shanghai Putai-A	603659 CH	139.36	15,307	128.4	56.7	38.3
Guangzhou Tinc-A	002709 CH	100.58	15,270	174.5	41.7	24.6
Ningbo Shansha-A	600884 CH	29.10	9,864	300.0	19.2	21.2
Shenzhen Capch-A	300037 CH	93.05	6,071	72.1	31.1	23.1
Chengdu Wintru-A	002539 CH	14.00	2,237	28.6	12.3	10.5
Guizhou Chanhe-A	002895 CH	25.49	1,969	75.7	36.6	20.7
Average				129.9	33.0	23.1

Sources: Bloomberg, OP Research

Exhibit 7: Polyimide is mainly used in semi-conductor, microelectronics, aerospace and etc




Sources: Company, OP Research

The production of high performance polyimide film was used to dominate by overseas manufacturers. Recently, Rayitek (688323 CH) become the first few domestic players in the high performance polyimide film market.

Tsaker will be one of the main beneficiaries from the growing domestic polyimide film industry if it could mass produce BPDA in the short term. This will be a new long-term growth driver for the Company.

### **Exhibit 8: Tsaker Chem's product line**



Sources: Company, OP Research

### Exhibit 9: Tsaker Chem's customers and its market share in certain chemical intermediates

Tsaker has over 10 years of working relationship with renowned international chemical manufacturers

SunChemical<sup>\*</sup>



ARCHROMA



We create chemistry



Tsaker has overwhelming market share in certain chemical intermediates


No.1
•DSD Acid(53%)
•DMSS(55%)

No.1 •DMAS(70%) No.1 •MNT(25%)

Sources: Company, OP Research

传化

### Exhibit 10: Tsaker's net profit continued to recover in 2H21




Sources: Company, OP Research



51.97%

Mr. Ge Yi

Sources: Company



48.03%

Public



## **Exhibit 15: Peer Group Comparison**

								3-Yr									
				3-mth				EPS						ROE	ROE	Sh px	
			Mkt cap	avg t/o	PER	PER	PER	Cagr		Div yld	Div yld	P/B	P/B	Hist	FY1	1-mth	Sh px
Company	Ticker	Price	(US\$m)	(US\$m)	Hist (x)	FY1 (x)	FY2 (x)	(%)	PEG(x)	Hist	FY1	Hist (x)	FY1 (x)	(%)	(%)	%	3-mth %
Tsaker Cham	1986 HK	1.31	172	0.2	7.6	5.1	3.9	27.5	0.2	3.6	19.80	0.6	0.6	5.1	11.0	-3.0	-13.2
HSI		22,901.56			9.1	10.8	9.5	(0.7)	(16.3)	2.6	3.23	1.0	1.1	10.5	10.5	-7.1	-7.2
HSCEI		8,030.90			8.5	8.6	7.7	1.9	4.7	2.9	3.52	0.9	1.1	10.4	12.2	-7.2	-8.7
CSI300		4,529.32			16.4	13.5	11.6	N/A	N/A	1.8	2.3	2.0	1.9	12.4	13.8	-5.4	-7.9
Peers																	
HK listed chemical co	mpanies				10.9	6.7	5.4	41.3	0.2	5.4	4.8	1.1	1.0	19.1	18.7	-4.3	-4.3
Dongyue Group	189 HK	189 HK	11.40	3,293	37.4	25.0	9.8	7.0	59.4	0.2	1.2	4.1	2.2	1.6	11.4	18.5	17.3
Yip'S Chemical	408 HK	408 HK	4.00	291	0.1	7.4	N/A	N/A	N/A	N/A	9.5	N/A	0.6	N/A	16.7	N/A	-9.1
Fufeng Group Ltd	546 HK	546 HK	2.95	957	1.9	9.6	5.3	4.6	33.4	0.2	4.7	6.3	0.5	0.5	7.1	9.5	-1.3
L & M Chemical	746 HK	746 HK	7.40	782	0.8	12.2	6.3	5.8	32.3	0.2	5.7	N/A	1.2	1.1	21.1	17.9	-2.5
China Risun Grou	1907 HK	1907 HK	4.83	2,746	2.3	9.3	5.5	4.3	40.1	0.1	5.7	4.1	1.6	1.5	33.9	28.7	1.7
China Sanjiang F	2198 HK	2198 HK	2.11	322	0.6	1.8	N/A	N/A	N/A	N/A	20.1	N/A	0.4	0.4	24.2	N/A	-10.2

<sup>\*</sup> Outliners and "N/A" entries are excl. from the calculation of averages

Sources: Bloomberg



# **Financial Summary**

(RMB mn)	FY17	FY18	FY19	FY20
Income Statement				
Revenue	1,247.4	1,515.9	1,818.3	1,275.3
<b>Gross Profit</b>	363.0	524.1	1,041.0	445.3
Other Operating Income(expenses)	(1.9)	(6.8)	(66.4)	(15.8)
Operating Expenses	(164.5)	(180.1)	(233.3)	(219.8)
Selling and marketing	(42.7)	(48.5)	(44.9)	(41.6)
General & admin	(121.8)	(131.6)	(188.4)	(178.2)
Operating Income (Loss)	196.6	331.7	741.3	209.7
Pretax Income	181.1	308.9	709.6	177.3
Income Tax Expense	(45.0)	(86.1)	(191.4)	(32.7)
Profit to shareholders	136.1	222.9	517.9	144.9
Balance sheet				
Total Assets				
Cash, Cash Equivalents & STI	359.8	124.3	104.8	101.2
Accounts & other Receivable	328.2	254.4	286.0	217.3
Inventories	115.0	210.0	274.2	177.8
Other ST Assets	174.9	286.2	191.3	151.2
Total Current Assets	977.9	875.1	856.4	647.5
Property, Plant & Equip, Net	1119.7	1,496.1	1,521.3	1,447.1
Other LT Assets	158.6	138.0	203.7	218.4
Total Noncurrent Assets	1,278.4	1,634.1	1,725.0	1,695.6
Total Assets	2,256.3	2,509.2	2,581.4	2,343.1
Liabilities & Shareholders' Equity				
Payables & Accruals	495.8	446.4	403.1	265.2
ST Debt	194.6	364.8	283.9	310.2
Other ST Liabilities	15.0	60.2	58.9	22.2
Total Current Liabilities	705.3	871.5	745.9	597.6
LT Debt	387.4	286.4	29.9	39.4
Other LT Liabilities	21.6	31.4	39.1	26.8
Total Noncurrent Liabilities	409.0	317.8	69.0	66.2
Total Liabilities	1,114.2	1,189.3	815.0	663.8
Share Capital & APIC	67.5	67.5	67.1	66.7
Retained Earnings	1,073.8	1251.5	1,699.1	1,612.6
Equity Before Minority Interest	1,141.3	1319.1	1,766.2	1,679.3
Minority Interest	0.6	0.8	0.3	0
Total Equity	1,141.9	1,319.9	1,766.4	1,679.3
Cash Flow Statement	· ·	·	•	
Cashflow from operating	191.6	216.7	564.9	219.2
Cashflow from investing	(257.3)	(463.1)	(213.7)	(39.4)
Cashflow from financing	27.6	10.0	(369.6)	(185.5)
Net cash changes	(38.1)	(236.4)	(18.4)	(5.6)
Sources: Pleambara, OR Research	·		·	

Sources: Bloomberg, OP Research



# **Our recent reports**

Date	Company / Sector	Stock Code	Title	Rating	Analyst
27/01/2022	Greentown Mgmt	9979	Resilient against headwinds	BUY	John Siah
21/01/2022	361 Degrees	1361	4Q21 retail sales beat expectation	BUY	John Siah
14/12/2021	Tian Lun Gas	1600	Embracing green energy, ambitious target for gas sales	BUY	John Siah
06/12/2021	New Higher Edu	2001	Aim for quality growth	BUY	John Siah
29/11/2021	China Edu Group	839	FY21 results in-line, expecting more M&A	BUY	John Siah
18/11/2021	Edvantage Group	382	FY21 results slightly beat our expectation	BUY	John Siah
26/10/2021	Truly Int'l	732	More added value of automotive display as a new earnings catalyst	BUY	John Siah
19/10/2021	China Edu Sector	-	Encourage private participation in vocational education	-	John Siah
11/10/2021	AAC Tech	2018	Sluggish 3Q21 earnings on weak smartphone market	BUY	John Siah
03/09/2021	HK Tech Venture	1137	Striving to become a global technology enabler	BUY	John Siah
31/08/2021	Tian Lun Gas	1600	Mixed 21H1 results, expecting margins to improve in 21H2E	BUY	John Siah
27/08/2021	AAC Tech	2018	Optics segment stood strong against headwinds in 21Q2	BUY	John Siah
25/08/2021	361 Degrees	1361	Strong earnings expected to continue in 21H2E	BUY	John Siah
09/08/2021	Edvantage Group	382	Promising growth to continue in FY22E	BUY	John Siah
09/08/2021	China Edu Group	839	Another landmark M&A	BUY	John Siah
09/08/2021	New Higher Edu	2001	SY21/22 growth on track	BUY	John Siah
06/08/2021	Innovent Bio	1801	Sintilimab on track to become RMB10 bn drug	BUY	Kevin Tam
05/08/2021	Greentown Mgmt	9979	Safe sail inside the Storm	BUY	John Siah
05/08/2021	Xinyi Energy	3868	More M&A coming in 21H2E	BUY	John Siah
30/07/2021	SF REIT	2191	First logistics REITs in HK, riding the e-commence wave	NR	John Siah
27/07/2021	China Edu Sector	-	Private Higher Edu will not be the next K12 tutoring	-	John Siah
13/07/2021	HKTV	1137	Edging up GMV with enabler business kicking off	BUY	Kevin Tam
07/07/2021	Xinyi Energy	3868	Fast growing solar farms with promising dividend outlook	BUY	John Siah
02/07/2021	Yidu Tech	2158	Getting closer to breakeven	BUY	Kevin Tam
24/06/2021	Greentown Mgmt	9979	21H1 net profit expected to up more than 70% YoY	BUY	John Siah
11/06/2021	TCL Electronics	1070	Turnaround possible in 2H21E	BUY	Kevin Tam
09/06/2021	Tian Lun Gas	1600	Zhuhai Port (000507.SZ) becomes new major shareholder	BUY	John Siah



#### TERMS FOR PROVISION OF REPORT, DISCLAIMERS AND DISCLOSURES

By accepting this report, you represent and warrant that you are entitled to receive such report in accordance with the restrictions set forth below and agree to be bound by the limitations contained herein. Any failure to comply with these limitations may constitute a violation of law or termination of such services provided to you.

#### Disclaimer

Research distributed in Hong Kong is intended only for institutional investors whose ordinary business activities involve investing in shares, bonds and associated securities and/or derivative securities and who have professional experience in such investments. Any person who is not an institutional investor must not rely on this communication.

The information and material presented herein are not directed at, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any jurisdiction where such distribution, publication, availability or use would be contrary to applicable law or regulation or which would subject Oriental Patron Securities Limited ("OPSL") and/or its associated companies and/or its affiliates (collectively "Oriental Patron") to any registration or licensing requirement within such jurisdiction.

The information and material presented herein are provided for information purposes only and are not to be used or considered as an offer or a solicitation to sell or an offer or solicitation to buy or subscribe for securities, investment products or other financial instruments, nor to constitute any advice or recommendation with respect to such securities, investment products or other financial instruments.

This research report is prepared for general circulation. It does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this report. This report is not to be relied upon in substitution for the exercise of independent judgment. Oriental Patron may have issued other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect the different assumptions, views and analytical methods of the analysts who prepared them. You should independently evaluate particular investments and you should consult an independent financial adviser before making any investments or entering into any transaction in relation to any securities mentioned in this report.

Information and opinions presented in this report have been obtained or derived from sources believed by Oriental Patron to be reliable, but Oriental Patron makes no representation as to their accuracy or completeness and Oriental Patron accepts no liability for loss arising from the use of the material presented in this report where permitted by law and/or regulation. Further, opinions expressed in this report are subject to change without notice. Oriental Patron does not accept any liability whatsoever whether direct or indirect that may arise from the use of information contained in this report.

The research analyst(s) primarily responsible for the preparation of this report confirm(s) that (a) all of the views expressed in this report accurately reflects his or their personal views about any and all of the subject securities or issuers; and (b) that no part of his or their compensation was, is or will be, directly or indirectly, related to the specific recommendations or views he or they expressed in this report.

Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance.

Oriental Patron, its directors, officers and employees may have investments in securities or derivatives of any companies mentioned in this report, and may make investment decisions that are inconsistent with the views expressed in this report.

#### **General Disclosure**

Oriental Patron, its directors, officers and employees, including persons involved in the preparation or issuance of this report, may, to the extent permitted by law, from time to time participate or invest in financing transactions with the issuer(s) of the securities mentioned in this report, perform services for or solicit business from such issuers, and/or have a position or holding, or other material interest, or effect transactions, in such securities or options thereon, or other investments related thereto. In addition, it may make markets in the securities mentioned in the material presented in this report. Oriental Patron may, to the extent permitted by law, act upon or use the information presented herein, or the research or analysis on which they are based, before the material is published. One or more directors, officers and/or employees of Oriental Patron may be a director of the issuers of the securities mentioned in this report. Oriental Patron may have, within the last three years, served as manager or co-manager of a public offering of securities for, or currently may make a primary market in issues of, any or all of the entities mentioned in this report or may be providing, or have provided within the previous 12 months, significant advice or investment services in relation to the investment concerned or a related investment or investment banking service to the issuers of the securities mentioned in this report.

#### Regulatory Disclosures as required by the Hong Kong Securities and Futures Commission

Oriental Patron (inclusive of OPSL) which are carrying on a business in Hong Kong in investment banking, proprietary trading or market making or agency broking are not a market maker in the securities of the subject companies mentioned in this report. Unless otherwise specified, Oriental Patron does not have any investment banking relationship with the companies mentioned in this report within the last 12 months. As at the date of this report, Oriental Patron do not have any interests in the subject company(ies) aggregating to an amount equal to or more than 1% of the subject company(ies) market capitalization.

#### **Analyst Certification:**

The views expressed in this research report accurately reflect the analyst's personal views about any and all of the subject securities or issuers; and no part of the research analyst's compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in the report.

## **Rating and Related Definitions**

**Buy (B)** We expect this stock outperform the relevant benchmark greater than 15% over the next 12 months.

Hold (H) We expect this stock to perform in line with the relevant benchmark over the next 12 months.

Sell (S) We expect this stock to underperform the relevant benchmark greater than 15% over the next 12 month.

Relevant Benchmark Represents the stock closing price as at the date quoted in this report.

#### Copyright © 2014 Oriental Patron Financial Group. All Rights Reserved

This report is being supplied to you strictly on the basis that it will remain confidential. Except as specifically permitted, no part of this presentation may be reproduced or distributed in any manner without the prior written permission of Oriental Patron. Oriental Patron accepts no liability whatsoever for the actions of third parties in this respect.



Tel: (852) 2135 0248

Fax: (852) 2135 0295